Activity and Safety of Nintedanib in the Treatment of Patients With Lymphangioleiomyomatosis
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Nintedanib for patients with lymphangioleiomyomatosis: a phase 2, open-label, single-arm study
Lancet Respir Med 2024 Oct 25;[EPub Ahead of Print], S Harari, D Elia, A Caminati, J Geginat, F Luisi, G Pelosi, C Specchia, O Torre, R Trevisan, C Vasco, M Zompatori, R CassandroFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.